Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2019.00907
Abstract: Bexarotene is a third-generation retinoid X receptor-selective retinoid that has been approved for use in the treatment of both early and advanced cutaneous T-cell lymphoma (CTCL). Although bexarotene has been used for decades in the… read more here.
Keywords: tumor; ccl22; production ccl22; bexarotene ... See more keywords